Bristol Myers Squibb says Alzheimer’s is the biggest market for new schizophrenia drug

CNBC January 15, 2025
Annika Kim Constantino

Key Points

– Bristol Myers Squibb believes Alzheimer’s treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in sales across different uses.

– Company executives said each treatment type they are studying has multibillion-dollar potential, including Alzheimer’s disease psychosis, agitation and cognition, along with bipolar disease and autism.

– Bristol Myers Squibb plans to release initial late-stage trial data on Alzheimer’s-related psychosis during the latter part of the year, which is earlier than expected.

Bristol Myers Squibb believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue.

In an interview, company executives...

Today's Sponsors

Today's Sponsor